Journal home
Advance online publication
Current issue
Archive
Press releases
Supplements
Focuses
Guide to authors
Online submissionOnline submission
For referees
Free online issue
Contact the journal
Subscribe
Advertising
work@npg
Reprints and permissions
About this site
For librarians
 
NPG Resources
Nature
Nature Reviews
Nature Immunology
Nature Cell Biology
Nature Genetics
news@nature.com
Nature Conferences
Dissect Medicine
NPG Subject areas
Biotechnology
Cancer
Chemistry
Clinical Medicine
Dentistry
Development
Drug Discovery
Earth Sciences
Evolution & Ecology
Genetics
Immunology
Materials Science
Medical Research
Microbiology
Molecular Cell Biology
Neuroscience
Pharmacology
Physics
Browse all publications
Article
Nature Medicine  8, 1427 - 1432 (2002)
Published online: 4 November 2002; | doi:10.1038/nm1202-795

Induction of angiogenesis in a mouse model using engineered transcription factors

Edward J. Rebar1, 3, Yan Huang2, 3, Reed Hickey2, Anjali K. Nath2, David Meoli2, Sameer Nath2, Bingliang Chen1, Lei Xu1, Yuxin Liang1, Andrew C. Jamieson1, Lei Zhang1, S Kaye Spratt1, Casey C. Case1, Alan Wolffe1 & Frank J. Giordano2

1  Sangamo Biosciences, Richmond, California, USA

2  Dept. of Medicine, Yale University School of Medicine, New Haven, Connecticut, USA

3  These authors contributed equally to this work.

Correspondence should be addressed to Frank J. Giordano fjg9@email.med.yale.edu
The relationship between the structure of zinc-finger protein (ZFP) transcription factors and DNA sequence binding specificity has been extensively studied1. Advances in this field have made it possible to design ZFPs de novo that will bind to specific targeted DNA sequences2, 3, 4, 5, 6, 7, 8, 9, 10. It has been proposed that such designed ZFPs may eventually be useful in gene therapy6, 7, 10. A principal advantage of this approach is that activation of an endogenous gene ensures expression of the natural array of splice variants2. Preliminary studies in tissue culture have validated the feasibility of this approach2, 3, 4. The studies reported here were intended to test whether engineered transcription factors are effective in a whole-organism model. ZFPs were designed to regulate the endogenous gene encoding vascular endothelial growth factor-A (Vegfa). Expression of these new ZFPs in vivo led to induced expression of the protein VEGF-A, stimulation of angiogenesis and acceleration of experimental wound healing. In addition, the neovasculature resulting from ZFP-induced expression of Vegfa was not hyperpermeable as was that produced by expression of murine Vegfa 164 cDNA. These data establish, for the first time, that specifically designed transcription factors can regulate an endogenous gene in vivo and evoke a potentially therapeutic biophysiologic effect.

 Top
Abstract
Previous | Next
Table of contents
Full textFull text
Download PDFDownload PDF
Send to a friendSend to a friend
Save this linkSave this link

Open Innovation Challenges

naturejobs

Competing financial interests
Figures & Tables
See also: News and Views by Pasqualini et al.
Export citation
natureproducts

Search buyers guide:

 
ADVERTISEMENT
 
Nature Medicine
ISSN: 1078-8956
EISSN: 1546-170X
Journal home | Advance online publication | Current issue | Archive | Press releases | Supplements | Focuses | For authors | Online submission | For referees | Free online issue | About the journal | Contact the journal | Subscribe | Advertising | work@npg | Reprints and permissions | About this site | For librarians
Nature Publishing Group, publisher of Nature, and other science journals and reference works©2002 Nature Publishing Group | Privacy policy